HIGHLIGHTS
- who: Muhammed Burak Demircan et al. from the Institute of Molecular Cell Biology, CMB, Jena University Hospital, Jena, Germany have published the article: Combined Activity of the Redox-Modulating Compound Setanaxib (GKT137831) with Cytotoxic Agents in the Killing of Acute Myeloid Leukemia Cells, in the Journal: Antioxidants 2022, 11, 513. of /2022/
- what: The authors have further investigated the effects of Setanaxib on AML cells. The authors focused on a potential additive value of Setanaxib when combined with cytotoxic agents. The authors propose that enhanced ROS formation by treatment with Setanaxib and daunorubicin contribute to . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.